Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Majadahonda – page 173

3 281 clinical trials in Majadahonda, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Majadahonda at a glance
3 281
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 281 trials in Majadahonda

Open in trial search

Study of Bemcentinib with Pembrolizumab, Carboplatin, and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with STK11 Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Bergenbio ASA

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3283142
  • Sponsor:Bayer AG

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:TIN816
  • Sponsor:Novartis Pharma AG

Bladder cancer

Not recruiting

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Grupo Espanol De Oncologia Genitourinaria-Socug

Neoplasm malignant

Not recruiting

Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study on NECVAX-NEO1 with PD-1/PD-L1 Inhibitors for Patients with Advanced Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Necvax-Neo1
  • Sponsor:NEC Bio Therapeutics GmbH

Uveal melanoma

Not recruiting

Study of Darovasertib and Crizotinib for Patients with Metastatic Uveal Melanoma Who Are HLA-A2 Negative

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Ideaya Biosciences Inc.

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Embolism

Not recruiting

Study on How REGN9933 and REGN7508 Help Prevent Blood Clots in Adults with a Peripherally Inserted Central Catheter (PICC)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Majadahonda

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on ATTR amyloid cardiomyopathy, evaluating new therapeutic approaches for both hereditary and wild-type variants of this heart condition.

  • Heart Disease Management
  • Cardiac Function Assessment
  • Disease Markers Evaluation

Multiple trials testing novel compounds to improve patient outcomes and quality of life.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting urinary tract infections and various herpes virus strains, including studies on both prevention and treatment.

  • UTI Prevention
  • Herpes Zoster Protection
  • Immunotherapy Development

Focus on long-term efficacy and immune response in different age groups.

03 Oncology Studies

Advanced research in multiple cancer types, including prostate cancer, gastric cancer, and lymphomas, with emphasis on targeted therapies and combination treatments.

  • Metastatic Disease Treatment
  • Novel Drug Combinations
  • Immunotherapy Approaches

Investigating breakthrough treatments for various stages of cancer progression.

04 Neurological Disorders

Pioneering research in cerebral ischemic stroke and multiple sclerosis, evaluating innovative treatments to improve patient outcomes and disease management.

  • Stroke Treatment
  • Progressive MS Management
  • Functional Recovery

Focus on both acute interventions and long-term disease modification.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.